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Bullous pemphigoid (BP) is an autoimmune skin
disease characterized by autoantibodies against the
hemidesmosomal protein BP180. In addition to IgG
autoantibodies, IgE class autoantibodies have been
reported in BP patients. Because animal models utiliz-
ing only IgG antibodies do not totally replicate human
BP, we examined the speci¢city and potential relevance
of IgE autoantibodies in this disease. Thirty BP patients
participated in these studies. Serum IgE was measured
and the IgE speci¢city was determined by immuno-
blotting. Double labeling Immuno£uorescence was per-
formed using combinations of speci¢c antibodies to
human mast cell tryptase, IgE and BP180. BP180-sti-
mulated histamine release was measured from basophils
of untreated BP patients (n¼ 9), BP patients undergoing
immunosuppressive therapy (n¼ 9) and controls
(n¼16). Elevated IgE levels were found In 70% of un-
treated BP patients. IgE autoantibodies directed against
BP180 were detected in 86% of untreated patients and in
all but one of these patients the IgE reacted with the
NC16A domain of BP180. IgE-coated mast cells were
detected in perilesional skin of the BP patients. More-
over, BP180 peptides were detected on these mast cells.
BP180-stimulated histamine release was signi¢cantly
higher in basophils obtained from untreated BP pa-
tients compared with control basophils (p¼ 0.006) or
from treated BP patients (p¼ 0.01). These ¢ndings sup-
port the hypothesis that IgE autoantibodies are involved
in the pathogenesis of BP. IgE and IgG BP autoantibo-
dies share the same antigenic speci¢city. Antigen-speci-
¢c degranulation of basophils and/or mast cells from
BP patients suggests a mechanism by which IgE may
contribute to lesion development. Key words: Bullous
pemphigoid/IgE/autoimmunity/collagenXVII. J InvestDermatol
120:784^788, 2003
B
ullous pemphigoid (BP) is an autoimmune disease
characterized by subepidermal blistering. The ¢rst
evidence of the immunologic basis of this disease was
obtained in 1967 by Jordon et al (1967). Immunoglobu-
lins and C3 were found to be deposited along the
basement membrane zone (BMZ) in the skin of BP patients.
Anti-BMZ antibodies of the IgG class were also found in the sera
of these patients.
BP180, a transmembrane member of the collagen protein fa-
mily (also designated type XVII collagen) has been shown to be
the primary antigenic target of BP autoantibodies (Diaz et al,
1990). BP180 is expressed on the basal surface of basal epidermal
keratinocytes and is a constituent of the hemidesmosomal com-
plex, a cellular structure that functions in dermal^epidermal ad-
hesion (Giudice et al, 1993). The major disease-associated epitopes
of BP180 have been mapped to the NC16A domain, a membrane-
proximal noncollagenous stretch of its ectodomain (Zillikens
et al, 1997).
Animal model studies have provided strong evidence that IgG
antibodies reactive with the NC16A domain of BP180 play a di-
rect role in the onset and progression of disease.When antibodies
generated against the murine ortholog of BP180 are injected into
neonatal BALB/C mice, the mice develop a skin disease with
many of the key immunopathologic features of BP (Liu et al,
1993). The development of lesions is dependent upon activation
of complement, recruitment of neutrophils, and release of pro-
teases, including neutrophil elastase and gelatinase B, at the lesion
site (Liu et al, 1995a, b, 1997, 1998, 2000). Two key features of the
human disease, however, are not reproduced in the BP mouse
model: eosinophilic in¢ltration of the dermis and spontaneous
blistering. In human BP, eosinophils are a regular histologic fea-
ture (Dvorak et al, 1982; Nishioka et al, 1984), whereas in the
mouse model the in¢ltrate is composed almost exclusively of
neutrophils. In the passive transfer mouse model, frictional pres-
sure is applied to the injection site in order to see detachment of
the skin grossly. In contrast, mechanical pressure is not recog-
nized as a strong contributor to blister development in BP. These
¢ndings led us to investigate whether autoantibodies of the IgE
class play a part in the development of the complete clinical
picture of BP.
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Whereas most work on BP has focused on IgG autoantibodies,
several previous studies have identi¢ed an IgE response in this
disease as well. IgE was detected at the cutaneous BMZ in 25%
of BP patients (Provost and Tomasi, 1974) and elevated circulating
IgE levels (with unknown speci¢cities) were observed in 70% of
BP patients (Arbesman et al, 1974; Bowszyc-Dmochowska et al,
2000). More recently, circulating IgE class antibodies against
BP180 were found in the majority of untreated BP patients
(Delaporte et al, 1996; Christophoridis et al, 2000; Dopp et al,
2000).
This study was designed to characterize further the pathologic
relevance of IgE antibodies in BP.We systematically evaluated 32
BP patients for the presence and speci¢city of IgE class autoanti-
bodies.We also examined the skin of these patients for the pre-
sence of dermal mast cells coated with anti-BP180 surface IgE.
Finally, circulating basophils obtained from these patients were
analyzed for the ability to degranulate in response to recombi-
nant BP180. Our data show that IgE class antibodies are present
in a large number of BP patients and that these autoantibodies
may play a part in the pathogenesis of the disease.
MATERIALS AND METHODS
Development of a panel of well characterized BP sera Thirty-
two patients with well-characterized BP took part in these studies, 23 of
whom had not received any immunosuppressive therapy prior to their
immunologic assessment. All patients had clinical and histologic
features characteristic of BP. In addition, all patients had direct
immuno£uorescence (IF) demonstrating IgG and/or C3 at the BMZ and
29 of 32 (91%) had initial positive indirect IF that showed IgG binding
the roof of NaCl split skin (Gammon et al, 1984). IgE levels were
measured in the serum of the patients by a human IgE capture enzyme-
linked immunosorbent assay quantitation kit (Bethyl Laboratories, Inc.
Montgomery,TX).
IF testing Circulating anti-BMZ autoantibodies were detected by
indirect IF using salt-split normal human skin as a substrate and serial
dilutions of the patient’s serum as a primary antibody. Fluorescein-
conjugated anti-human IgG or IgE was used as a secondary antibody.
For direct IF, 4 mm cryosections of perilesional BP skin (or controls)
were incubated with the £uorescein isothiocyanate (FITC) conjugated
anti-human IgG (g-chain speci¢c) or IgE (e-chain speci¢c) for 30 min at
room temperature. After washing, the slides were viewed with a Nikon
photomicroscope equipped for epi£uorescence.
Skin sections from BP patient biopsies (n¼ 5) were double labeled with
Texas red conjugated anti-human mast cell tryptase and either FITC-anti-
human IgE (e chain speci¢c), FITC-anti-human IgG (g chain speci¢c) or
HD18, a monoclonal anti-human BP180 antibody (Polha-Gubo et al, 1995).
As an additional control, double labeling experiments were performed
with an additional monoclonal antibody of the same subclass against
another component of the BMZ, the a-3 chain of laminin 5. The sections
were examined with both FITC (GFP) and Texas Red (DM580) ¢lters and
images were taken with a SPOT RT camera. The two images were
superimposed using SPOT RT software in order to identify cells labeled
with both conjugates.
Immunoblotting of recombinant proteins and skin extracts The
recombinant NC16A domain of BP180 was prepared as previously
described (Zillikens et al, 1997). A⁄nity puri¢ed recombinant NC16A
peptide or human keratinocyte extracts were electrophoresed on sodium
dodecyl sulfate^polyacrylamide gels and immunoblotting was carried out
using a standard protocol (Zillikens et al, 1997).
Histamine release by BP patient basophils (Botulinska et al,
1999) Histamine release from peripheral blood basophils in response to
the NC16A domain of BP180 was measured using a commercially
available competitive immunoassay (Immunotech, Fullerton, CA).
Peripheral blood was drawn from 34 subjects: 16 normal volunteers, nine
untreated BP patients with active disease, and nine BP patients who were
treated and had minimal or no disease activity. Controls were 16 age-
matched patients with other skin diseases. These included seven patients
with autoimmune diseases other than pemphigoid: pemphigus vulgaris
(n¼ 4), pemphigus foliaceus (n¼ 2), and lupus erythematosus (n¼1).
Other controls had a variety of other in£ammatory or neoplastic skin
disorders. Because no di¡erences were seen in any measurement between
these two subsets of the control group they were combined for analysis.
The blood was exposed to the NC16A domain of BP180, 10 mg per ml,
and incubated for 30 min at 371C. Aliquots of the samples were also
treated with ionomycin (nonimmunologic release), bu¡er only
(spontaneous histamine release), or lyzed in distilled water (total
histamine content). The NC1 region of collagen VII (gift of Drs David
Woodley and Mei Chen, University of Southern California) or GST
alone served as additional controls. The histamine samples and controls
were acylated and the histamine content was measured by competitive
histamine immunoassay. After incubation, the wells were washed and
bound tracer was detected with the chromogen pNPP. Histamine
concentration in the experimental samples was determined by comparison
with a standard curve utilizing standards supplied with the kit. The
samples were corrected for spontaneous release. One control sample was
eliminated from analysis because of spontaneous release in excess of 5%.
Statistical analysis Serum IgE levels were compared by the Wilcoxon
rank sum test between the untreated BP patients, treated BP patients and
controls. The ratio of histamine release by NC16A to the background
histamine release was compared among the untreated BP patients, treated
patients and controls using the Wilcoxon rank sum test. The Mann^
Whitney median con¢dence interval was used to give a nonparametric
estimate of the relative size of the histamine ratios for the three groups.
All calculations were performed with SAS statistical software (The SAS
Institute, Cary, NC).
RESULTS
BP patients have elevated serum IgE Levels The results of
the serum IgE measurements are shown in Fig 1. The serum
IgE level was elevated in 16 of 23 untreated patients (70%). The
mean IgE level of the untreated patients was 399 IU (range
37^1766) with a normal range for this assay of 0^120 IU per ml.
The controls from our outpatient clinic (n¼17) had a mean IgE
level of 31 IU and no control patient had an IgE level above 120
IU. This was a statistically signi¢cant di¡erence between controls
and untreated patients (po0.0001). Only three of the nine
partially treated patients had IgE levels 4120 IU. Whereas the
mean IgE level of the treated patients still showed some
elevation with a mean serum IgE of 213 IU, this was only
marginally signi¢cant when compared with the controls
(p¼ 0.0125).
Figure1. Serum IgE levels in untreated BP patients (n= 23), treated
patients (n= 9), and controls (n= 17). Serum IgE levels in untreated BP
patients were signi¢cantly above the control group (po0.0001). Three of
the BP patients who were treated still had levels above the established
upper limit of normal in this assay, 120 IU per ml. The mean IgE level of
the control patients was 31 IU per ml and none of the controls had an IgE
level above the upper limit of normal for the assay.
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IgE reactivity with the NC16A domain of BP180 is present
in BP sera The sera of 30 BP patients were tested by
immunoblotting for IgE reactivity against the NC16A domain
of BP180. Of the 23 untreated BP patients, 16 (70%) had
detectable IgE antibodies that reacted with BP180 (Fig 2). The
reactivity was with NC16A in 15 of 16 of these patients. One
untreated patient whose IgE did not bind NC16A reacted with
BP180 protein extracted from human keratinocytes, suggesting
this patient reacted with sites on BP180 other than NC16A. In
addition, four of seven of the treated patients also had IgE class
antibodies that bound to NC16A (57%). These four all reacted
with NC16A. Sixteen controls (detailed under histamine release)
did not react with NC16A.
BP patients have circulating IgE that binds the BMZ but
in-vivo IgE is bound to dermal cells Direct IF testing for
IgE was performed on perilesional skin of 23 patients in whom
biopsy specimens were available and indirect IF on all 32 sera.
Whereas no IgE BMZ staining was identi¢ed by direct IF, 15 of
18 untreated patients’ biopsies showed cells in the papillary
and reticular dermis that stained strongly with FITC anti-IgE
(Fig 3A) and two of ¢ve patients who had received some
immunosuppressive treatment prior to biopsy also had cellular
staining. In contrast, staining of 102 control samples (skin
biopsies submitted to the Clinical Immunodermatology
Laboratory with negative routine IF) showed only eight with
any detectable cellular staining with anti-IgE. Indirect IF
identi¢ed seven of 23 untreated sera that contained circulating
IgE class antibodies that bound to the BMZ. No treated patient
had detectable circulating anti-BMZ IgE.
Mast cells in the dermis of BP patients are opsonized with
IgE and have surface-bound BP180 To verify that the cells
labeled with anti-IgE in the dermis of BP patients were mast
cells, cryosections from ¢ve biopsies that had shown cellular
staining in the dermis were double labeled with anti-human IgE
and anti-human mast cell tryptase. All ¢ve specimens showed
double labeling of the cells with IgE and tryptase, indicating
they were mast cells (not shown). Having demonstrated that
IgE-coated mast cells are a common feature in the skin of BP
patients, we looked for the presence of antigen on the surface of
these cells. The same ¢ve biopsies were double labeled with anti-
human mast cell tryptase and HD-18, a monoclonal antibody
that recognizes BP180 (Polha-Gubo et al, 1995). Cells that labeled
with both the antibodies to tryptase and HD-18 were found in
¢ve of ¢ve BP biopsies (Fig 3B). This suggests that mast cells in
the dermis of BP patients have BP180-speci¢c IgE on their
surface and that antigen is also present on the surface of the
cells. The control monoclonal antibodies against the a3 chain of
laminin 5 labeled the BMZ of the biopsies. No dermal cells
labeled with the anti-laminin 5 antibody and no double labeling
with anti-human tryptase and anti-laminin 5 was seen in any of
these biopsies (data not shown).
In order to ensure that the binding of BP180 on the surface of
the mast cells was due to IgE rather than IgG (as under rare
circumstances mast cells can express the IgG receptor, FcgRI
(Okayama et al, 2000), we double labeled skin biopsies from BP
patients (n¼ 5) with FITC conjugated anti-IgG (g-chain speci¢c)
and anti-human mast cell tryptase. No double-labeled cells
were seen in any of the biopsy specimens (not shown). In
addition, the cells on direct IF that bound anti-IgE did not react
with anti-IgG.
Figure 3. Direct IF of perilesional BP skin. (A) Skin biopsy from a BP
patient stained with anti-human IgE. No reactivity is visible at the BMZ,
however, numerous cells in the dermis are stained. (B) Double immuno-
£uorescent labeling of the same specimen with anti-human mast cell tryp-
tase and a monoclonal antibody against BP180, HD-18. The BMZ stains
green with HD-18 due to the presence of BP180 that is normally present.
The yellow cells in the dermis (arrows) are labeled with both anti-human
mast cell tryptase and HD-18.This indicates that these mast cells have frag-
ments of BP180 on their surface.
Figure 2. BP IgE reactivity with BP180 NC16A fusion protein. Sera
of 30 BP patients were tested for IgE reactivity against the NC16A domain
of BP180 by immunoblotting. This representative blot shows the reactivity
of sera from three BP patients. The sera were tested against NC16A (lanes
marked N) and GST (lanes marked G). Arrows on the left indicate the ex-
pected location of reactivity with NC16A or GST. BP patients An-4 and
Jo-8 both demonstrate strong IgE reactivity with NC16A and none with
GST.The third patient, Ho-12, showed no reactivity with either NC16A or
GST. Sixteen of 23 untreated BP patients had detectable IgE antibodies that
reacted with NC16A, and four of seven treated patients also had IgE anti-
bodies against NC16A.
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Basophils from untreated BP patients release histamine in
response to exposure to recombinant NC16A As it was not
feasible to extract mast cells from BP skin to test directly their
degranulation in response to NC16A, histamine release from
peripheral blood basophils in response to the NC16A domain of
BP180 was measured (Fig 4). The ratio of the NC16A stimulated
release to spontaneous release was found to be signi¢cantly
higher in the untreated BP patients when compared with the
control population (2.51 vs 0.872, p¼ 0.0006) and with the
treated patients (2.51 vs 1.031, p¼ 0.01). No signi¢cant di¡erence
was seen in the release by treated BP patients and controls (1.031
vs 0.872, p¼ 0.29). The untreated BP patients were marginally
older than the controls (p¼ 0.07); however, there was no
relationship between age and histamine release ratios.
Of the nine untreated patients, seven showed an increase in
histamine release above baseline in response to NC16A. Five of
the nine untreated patients that were tested for histamine release
had IgE directed against NC16A detected by immunoblotting.
All ¢ve of these patients showed increased histamine release in
response to NC16A. In addition, two patients in whom we were
unable to detect NC16A-speci¢c IgE by blotting techniques
also showed some release when challenged with NC16A.
Interestingly, one of the untreated patients that showed no
histamine release above spontaneous with NC16A did not react
with the NC16A domain of BP180 by enzyme-linked
immunosorbent assay or western blot. This patient does,
however, react with the entire BP180 protein extracted from
normal human keratinocytes, suggesting that this patient’s serum
recognizes a region of BP180 other than the NC16A domain.
DISCUSSION
The classic role for IgE class antibodies in the immune response is
in allergic and parasitic diseases. More recently a role for IgE in
autoimmune disease has been postulated but its part in autoim-
munity has not been elucidated. Most work regarding IgE in
autoimmunity thus far has been on the role of autoantigens in
atopic dermatitis and in animal models, such as the £aky skin
mutant mouse and mercury-induced autoimmunity in rats
(Pelsue et al, 1998; Seiberler et al, 1999; Gorrie et al, 2000). Interest-
ingly, IgE class autoantibodies against thyroid peroxidase have
recently been identi¢ed in patients with Graves’ disease and
Hashimoto’s thyroiditis (Guo et al, 1997; Sato et al, 1999), but their
pathogenic signi¢cance remains unknown. Our study provides
further evidence that IgE may be involved in the development
of human organ-speci¢c autoimmune diseases.
Several ¢ndings now implicate IgE class autoantibodies in the
pathogenesis of BP. In this study we found that 70% of the un-
treated BP patients had elevated total IgE levels, a number that is
similar to that reported by other authors (Arbesman et al, 1974;
Bowszyc-Dmochowska et al, 2000). We also showed that these
IgE autoantibodies react with the same antigenic target as that
of the IgG class autoantibodies. Further, the IgE of most BP pa-
tients reacted with the same region of the BP180 protein, NC16A,
that has been shown to be of pathogenic relevance with IgG class
autoantibodies. Dendritic cells can express the FceRI under
certain disease conditions and may utilize this receptor to present
IgE-de¢ned antigens to T cells (Kraft et al, 1998). Autoantibodies
against the FceRIa have also been identi¢ed in 20% of BP pa-
tients (Fiebiger et al, 1998). In contrast to the anti-BP180 IgE anti-
bodies we have identi¢ed, these IgG autoantibodies did not cause
histamine release from mast cells (Fiebiger et al, 1998). The way in
which these autoantibodies against the IgE receptor may contri-
bute to the pathogenesis of BP is unknown.
The presence of IgE autoantibodies in BP is particularly inter-
esting in light of the fact that BP patients typically have an early
urticarial phase of the eruption. During this time the patients
have large urticarial plaques but may manifest few if any blisters.
Sequential histologic examination of the skin of BP patients dur-
ing the development of individual lesions has shown that mast
cell degranulation is an early event followed by eosinophil migra-
tion into the lesion (Wintroub et al, 1978; Dvorak et al, 1982). The
role of IgE-mediated degranulation of mast cells in allergic forms
of urticaria is well established (Friedmann, 1999).Wheals of short
duration are caused by histamine, whereas the involvement of
other mediators may produce eruptions of longer duration. In ad-
dition, mast cell degranulation and release of tryptase can cause
separation of the epidermal^dermal junction experimentally
(Kaminska et al, 1999).
In contrast to a previous report, we rarely found IgE at the
BMZ by direct IF. This older report used polyclonal antibodies
against IgE, and their lack of reactivity with other immunoglo-
bulin classes was not demonstrated (Provost and Tomasi, 1974). As
indirect IF identi¢ed some patients with circulating IgE capable
of binding the BMZ, the negative results on standard direct IF
most likely represent a lack of sensitivity compared with salt-split
indirect IF.
Skin biopsies of our untreated BP patients showed IgE coating
the surface of dermal mast cells. Moreover, many of these mast
cells also labeled with a monoclonal antibody against BP180, in-
dicating that BP180 or fragments thereof are bound to the surface
of dermal mast cells in BP. This suggests that BP180-speci¢c IgE
coating the surface of mast cells results in their degranulation
when exposed to BP180 peptides. Cleavage of BP180 into smaller
polypeptides is part of its normal processing (Schacke et al, 1998;
Hirako, 1998; Schumann et al, 2000) and may provide a source of
BP180 peptides to the mast cells. Alternatively, disruption of the
BMZ by IgG binding may cause release of antigen. Whereas it
was not possible to test directly the response of patients’ skin mast
cells to BP180, the fact that circulating basophils from untreated
BP patients released histamine in response to recombinant
NC16A suggests that anti-BP180 IgE is capable of binding to cells
that express FceRI on their surface.
These data support the possibility that IgE class antibodies play
a part in the pathogenesis of BP. Acting in concert with IgG class
antibodies they may produce the complete spectrum of the BP
phenotype. Further work with puri¢ed IgE is planned to identify
more directly its role in BP.
This work was supported by a Merit ReviewAward from theVeterans Administration
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Figure 4. NC16A stimulated histamine release from circulating ba-
sophils. Circulating basophils were incubated with 10 ng of NC16A and
histamine release was measured by competitive immunoassay. Results with
expressed as the percent of background. Untreated BP patients showed a
statistically signi¢cant release of histamine in response to NC16A when
compared with controls (p¼ 0.006). No signi¢cant di¡erence was seen in
the release from treated BP patients and the control patients. No release
above baseline was seen in the 16 age-matched controls.
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